Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: atherosclerosis

January 26, 2022 CD as API / CD derivatives / Pharma applications

Poly-β-cyclodextrin Supramolecular Nanoassembly with a pH-Sensitive Switch Removing Lysosomal Cholesterol Crystals for Antiatherosclerosis

Cholesterol crystals (CCs), originally accumulating in the lysosome of cholesterol-laden cells, can aggravate the progression of atherosclerosis. β-cyclodextrin (CD) is

Continue reading

January 6, 2022 CD as API / Pharma applications

Beta-Cyclodextrin/L-Arginine/Au Nanomotors for Atherosclerosis

Most of the current non-pharmacological treatment strategies for atherosclerosis (AS) suffer from poor penetration into the plaque and only aim

Continue reading

September 27, 2021 CD as API / CD derivatives / Pharma applications

Underdog Closes $10M Financing Round – the next cyclodextrin can be developed further as active

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.

Continue reading

September 9, 2021 CD as API / CD derivatives / Pharma applications

Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators

Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been

Continue reading

April 27, 2021 CD as API / CD derivatives / Pharma applications

Cyclodextrin dimers: a versatile approach to optimizing encapsulation and their application to therapeutic extraction of toxic oxysterols

A novel class of specifically engineered, dimerized cyclodextrin nanostructures was developed for the encapsulation of toxic biomolecules such as 7-ketocholesterol

Continue reading

July 15, 2020 CD as API / CD derivatives / Pharma applications

Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol

SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class

Continue reading

June 19, 2020 CD as API / CD derivatives / Pharma applications

Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition

Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed

Continue reading

April 27, 2020 CD as API

Is CD shuttle or sink for cholesterol?

A Chinese group has recently published [1] their interesting findings: in atherosclerosis β-CD (probaly methyl beta-cyclodextrin, but not specified) was

Continue reading

January 14, 2020 CD as API

Cyclodextrin polymer of reduced ototoxicity improves atherosclerosis therapy

Although CD has been engineered into various nano-sized formulations, their main role was to incorporate a drug of interest for

Continue reading

November 20, 2019 CD as API / CD derivatives / Pharma applications

Underdog Launches With $4M to Target “Toxic” Form of Cholesterol

Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • Update: FDA approves HPBCD-enabled tecovirimat against pox virus
  • Life cycle of Tecovirimat authorized to treat human monkeypox infection in EU has been extended by reformulation with HPBCD by the originator Siga Technologies.
  • pH-Responsive templates modulate the dynamic enzymatic synthesis of cyclodextrins
  • Hadakara medicinal deodorant body soap
  • Statistics on CD-containing cosmetic products in the US

Tags

antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis Trappsol wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (25)
  • CD as API (174)
  • CD derivatives (223)
  • Cosmetics and toilettry (17)
  • Drug delivery (340)
  • E-ducation (49)
  • Environmental (61)
  • Events (142)
  • Food (97)
  • Gene delivery (6)
  • In Hungarian (4)
  • Life sciences (8)
  • Non-pharma applications (158)
  • Other industrial use (49)
  • Pharma applications (575)
  • Supramolecular systems (18)
  • Uncategorized (32)

Top Posts

  • pH-Responsive templates modulate the dynamic enzymatic synthesis of cyclodextrins
  • Update: FDA approves HPBCD-enabled tecovirimat against pox virus
  • Life cycle of Tecovirimat authorized to treat human monkeypox infection in EU has been extended by reformulation with HPBCD by the originator Siga Technologies.
  • 10th Asian Cyclodextrin Conference (ACC2019)
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Pilocarpine eye drops (Vuity)
  • Cholesterol/β-cyclodextrin complexation revisited by combined experimental and computational approaches
  • Nasal delivery with beta-cyclodextrin is approved; a short story of Baqsimi
  • International Conference on Bioinspiration and Biobased​ Materials
  • Cyclodextrins in soft drinks

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 417 other subscribers

 

Loading Comments...